How to set up a contrast-enhanced ultrasound service
- 215 Downloads
This paper will provide practical details and useful information on how to establish a contrast-enhanced ultrasound (CEUS) service safely and efficiently. It is meant to be an introduction to CEUS focusing on how to implement ultrasound contrast into a clinical service rather than on specific clinical applications. Ultrasound contrast agents have been in use throughout most of the world and have been used off-label in the United States for over a decade. In addition to the use of ultrasound contrast agents in cardiac imaging, the FDA recently approved their use in liver imaging for both pediatric and adult patients, and for use in the urinary tract (voiding ultrasonography) in pediatric patients for evaluation of suspected or known vesicoureteral reflux (VUR) [1, 2, 3, 4, 5, 6, 7, 8]. With recent FDA approvals, even wider adaption of CEUS is expected.
Contrast-enhanced ultrasound has an excellent safety profile. Since the contrast agents are excreted by the lungs they are...
Compliance with ethical standards
No funding was obtained for this study.
Conflict of interest
The authors have no conflict of interest to disclose.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Lumason (sulfur hexafluoride lipid –type A microspheres) for injectable suspension full Perscribing Information. Monoroe Township, N.B.D.I.M. http://imaging.bracco.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason.
- 2.Optison (perflutren protein-type A microspheres) for injectable suspension full prescribing information. Malborough MA: GE Healthcare, M. http://www3.gehealthcare.com/en/products/categories/contrast_media/optison.
- 3.Definitiy (perflutren protein-type A microspheres) for injectable suspension full prescribing Information, N.B., MA: Lantheus Medical Imaging; April 2013. http://www.definityimaging.com/main.html?
- 10.Claudon M, et al. (2013) Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 39(2):187–210CrossRefPubMedGoogle Scholar
- 18.Karthikesalingam A, Al-Jundi E, Jackson D, et al. (2012) Systematic review and meta-analysis of duplex ultrasonography, contrast-enhanced ultrasonography or computed tomography for surveillance after endovascular aneurysm repair. J Surg 99(11):1514–1523Google Scholar
- 21.Quaia E, Cabibbo B, De Paoli L, et al. (2013) The value of time-intensity curves obtained after microbubble contrast agent injection to discriminate responders from non-responders to anti-inflammatory medication among patients with Crohn’s disease. Eur Radiol 23(6):1650–1659CrossRefPubMedGoogle Scholar
- 22.Quaia E, Migaleddu V, Baratella E, et al. (2009) The diagnostic value of small bowel wall vascularity after sulfur hexafluoride-filled microbubble injection in patients with Crohn’s disease. Correlation with the therapeutic effectiveness of specific anti-inflammatory treatment. Eur J Radiol 69(3):438–444CrossRefPubMedGoogle Scholar
- 24.Averkiou M, Bruce M, Jensen S, Rafter P, Brock-Fisher T, Powers J. Pulsing schemes for the detection of nonlinear echoes from contrast microbubbles. In:Proceedings of the 9th European Symposium on Ultrasound Contrast Iaging 2004; Rotterdam, The Netherlands.Google Scholar
- 26.Aoki S, Hattori R, Yamamoto T, Funahashi , et al. (2010) Contrast-enhanced ultrasound using a time-intensity curve for the diagnosis of renal cell carcinoma. BHUI 108:349–354Google Scholar
- 29.http://imaging.bracco.com/sites/braccoimaging.com/files/technica_sheet_pdf/us-en-2017-01-11-pr-lumason-contraindication.pdf, created 1/11/2017, Accessed 6/16/2017